上海
上海，2026年7月22日 – 药明康德今日宣布，公司连续第四年入选“富时罗素社会责任指数系列”（FTSE4Good Index Series），这一认可体现了公司对可持续发展的坚定承诺。
富时罗素社会责任指数系列由全球指数和数据提供商富时罗素（FTSE Russell）设立，旨在评估和跟踪在可持续发展方面表现卓越的公司。该指数为投资者提供参考基准，引导企业优化经营行为，并支持投资者构建符合其价值理念的投资组合。在本次评估周期中，药明康德在企业治理、反腐败和劳工标准三项主题均获满分5分。
“很荣幸再次入选富时罗素社会责任指数系列，这体现了资本市场对药明康德的可持续发展管理充满信心。”药明康德联席首席执行官兼可持续发展委员会主席杨青博士表示：“我们将持续加强负责任的商业实践，支持全球医药健康产业的可持续发展，帮助客户推动更多突破性疗法早日上市，早日实现‘让天下没有难做的药，难治的病’的伟大愿景。”
作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德和大多数客户一样，积极践行对可持续发展的承诺。截至目前，公司已获得多家国际权威可持续发展评级机构的认可，包括MSCI ESG “AAA”级；CDP气候变化、水安全及供应商参与“A”级榜单；EcoVadis企业社会责任“金牌”；入选道琼斯领先全球指数和S&P Global《可持续发展年鉴》；ISS ESG “Prime”表彰。
此外，药明康德不断深化可持续发展承诺，公司温室气体减排近期目标成功通过了SBTi审核认证；公司已加入联合国全球契约组织（UNGC），承诺支持全球契约十项原则，同时加入制药供应链倡议（PSCI），成为PSCI供应商合作伙伴。
关于药明康德
药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com。
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year
SHANGHAI, July 21, 2026 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announced it has been named in the FTSE4Good Index Series for the fourth consecutive year, reflecting the Company’s sustained commitment to sustainability.
The FTSE4Good Index Series, created by the global index and data provider FTSE Russell, is a family of equity indices designed to assess and track the performance of companies demonstrating strong sustainability practices, serving as a benchmark for investors seeking to encourage positive change in corporate behavior and align their portfolios with their values. In the most recent assessment cycle, WuXi AppTec achieved the highest score of 5 points in Corporate Governance, Anti-Corruption, and Labor Standards.
“We are honored to be recognized once again as a constituent of the FTSE4Good Index Series. This acknowledgement affirms the capital markets’ confidence in WuXi AppTec’s sustainable management practices,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s Sustainability Committee. “We will continue to strengthen our responsible business practices and support the sustainable development of the global pharmaceutical industry, while advancing our vision that ‘every drug can be made, and every disease can be treated.’”
As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates sustainability throughout its operations in alignment with the values of its customers and partners. The Company’s sustainability performance has received notable recognition from leading global sustainability rating agencies, including “AAA” rating in MSCI; “A List” from CDP Climate Change, Water Security, and Supplier Engagement; “Gold” medal in EcoVadis Sustainability Rating; selection for Dow Jones Best-in-Class World Index and S&P Global Sustainability Yearbook; “Prime” award in ISS ESG Corporate Rating.
Furthering its sustainability commitments, WuXi AppTec’s near-term greenhouse gas emissions reduction targets have been validated by the Science Based Targets initiative (SBTi). The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).
About WuXi AppTec
WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.
免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。
版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
